Angststörungen
Studienlage · Detail RCT (parallel, double-blind) · Angststörungen · 2019

Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test

Gemischt GRADE Moderat 233 Zitate
Stichproben = 57 Pat.
DauerEinzeldosis
KontrollePlacebo
EndpunktVAMS
Verblindungdoppelblind
DesignRCT (parallel, double-blind)
Cannabinoidcbd
Max. Dosis600.0 mg
Applikationoral
Kernaussage

CBD 300 mg reduzierte Angst signifikant, höhere und niedrigere Dosen zeigten keine Wirkung gegenüber Placebo (umgekehrte U-Kurve).

Zusammenfassung

n=57 gesunde männliche Probanden, CBD 150/300/600 mg vs. Placebo bei simuliertem Redeangst-Test (SPST); nur 300 mg CBD reduzierte Angst signifikant vs. Placebo (VAMS p<0.05); 150 mg und 600 mg zeigten keinen signifikanten Unterschied zu Placebo — umgekehrte U-förmige Dosis-Wirkungs-Kurve.

P
PopulationGesunde männliche Probanden, n=57
I
InterventionOrales CBD 150 mg, 300 mg oder 600 mg (Einmaldosis)
C
KontrollePlacebo (oral)
O
OutcomeNur 300 mg CBD reduzierte Angst signifikant gegenüber Placebo (VAMS); 150 mg und 600 mg zeigten keine signifikanten Unterschiede zu Placebo
Vertrauen in die Evidenz
Moderat

Dritte von vier GRADE-Stufen, die Effektschätzung ist wahrscheinlich verlässlich.

Herabgestuft wegen
Ungenauigkeit
Qualitätsprofil
Größe
Verblindung Doppelblind
Effektstärke Gemischt
Zitate / Jahr
Autoren
Linares I M, Zuardi A W, Pereira L C et al.
DOI 10.1590/1516-4446-2017-0015
Design: RCT (parallel, double-blind)
Teilen
Abstract
<h4>Objective</h4>Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves. No study, however, has investigated whether increasing doses of this drug would also cause similar curves in humans. The objective of this study was to compare the acute effects of different doses of CBD and placebo in healthy volunteers performing a simulated public speaking test (SPST), a well-tested anxiety-inducing method.<h4>Method</h4>A total of 57 healthy male subjects were allocated to receive oral CBD at doses of 150 mg (n=15), 300 mg (n=15), 600 mg (n=12) or placebo (n=15) in a double-blind procedure. During the SPST, subjective ratings on the Visual Analogue Mood Scale (VAMS) and physiological measures (systolic and diastolic blood pressure, heart rate) were obtained at six different time points.<h4>Results</h4>Compared to placebo, pretreatment with 300 mg of CBD significantly reduced anxiety during the speech. No significant differences in VAMS scores were observed between groups receiving CBD 150 mg, 600 mg and placebo.<h4>Conclusion</h4>Our findings confirm the anxiolytic-like properties of CBD and are consonant with results of animal studies describing bell-shaped dose-response curves. Optimal therapeutic doses of CBD should be rigorously determined so that research findings can be adequately translated into clinical practice.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel